Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.

Yeokyeong ShinBo Hyun MoonBaek-Yeol RyooHeung-Moon ChangKyu-Pyo KimYong Sang HongTae Won KimJin-Sook RyuYong-Il Kim Changhoon Yoo

Published in: Targeted oncology (2023)

In Korean patients with advanced NETs, Lu-177 DOTATATE PRRT showed efficacy and safety outcomes, consistent with those in the NETTER-1 trial and previous Western real-world studies.

Keyphrases

neuroendocrine tumors
squamous cell carcinoma
small cell lung cancer
study protocol
phase iii
locally advanced
clinical trial
south africa
phase ii
case control
randomized controlled trial
radiation therapy
open label
adipose tissue
binding protein
metabolic syndrome
bone marrow
skeletal muscle
double blind